Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Effective Management of Schizophrenia: Evidence-Based Treatments and Shared Decision-Making


     

Content Overview 

This activity will educate clinicians about the use of evidence-based treatments for the effective management of schizophrenia. The activity provides a thorough analysis of currently available oral and injectable medications used in the treatment of schizophrenia.  It also examines team-based approaches to the development of patient-centered treatment plans, strategies for overcoming treatment barriers, and the use of evidence-based practices to guide treatment interventions.  Finally, there will be an optional live workshop offered October 14, 2020 for participants who have completed the online modules and would like a case-based opportunity to practice applying the information with the guidance/feedback of course faculty.  The workshop will also include ample time for facilitators to address participant questions.  
 

Overall Learning Objectives
  • Examine currently available oral and long-acting injectable (LAI) antipsychotics for the treatment of schizophrenia.
  • Identify considerations for the proper administration of intramuscular injections. 
  • Discuss the development and use of recovery plans in the effective management of schizophrenia.  
  • Examine key considerations for overcoming treatment barriers in the treatment of schizophrenia.  
  • Explain the use of evidence-based practices to evaluate medication interventions in schizophrenia. 
 

Activity Format  
  • This continuing education activity consists of 5 self-paced online modules (total 4.25 CE hours) plus an optional live case-based workshop (3 CE hours) facilitated by course faculty.  Specific sessions listed at the bottom of the page.
  • To earn CE credit for each self-paced online module:  learners must complete the pre-test (not graded), view the video presentation and PDF handout, complete the post-test (score > 70% within three attempts), and complete the online evaluation.   
  • To earn CE credit for the live workshop:  learners must participate in the faculty-guided case exercises (3 hours) and complete the online evaluation at the conclusion of the workshop.
  • The live in-person workshop is currently scheduled to take place October 14, 2020 (time TBD) in Austin, Texas as a pre-conference activty at The University of Texas College of Pharmacy's 2020 Psychiatric Pharmacotherapy Update.  Live streaming/virtual attendance of the workshop will be explored; more information posted by September.    
  • Pharmacist learners:  CE credit will be uploaded directly to your NABP CPE Monitor profile within a few days of completing an evaluation; contact UT Continuing Pharmacy Education if you experience a problem:  UTpharmacyCE@austin.utexas.edu  (NOTE:  pharmacists must notify UT Continuing Pharmacy Education about CE credit corrections within 60 days of module/workshop completion or credit will be forfeited).
  • All other learners CE:  select "View/Print CE Credit" at top of page to view your updated certificate or completed credit hours as you complete each evaluation.
 

Scientific Chair
 
Stephen R. Saklad, PharmD, BCPP
Director and Clinical Professor
Psychiatric Pharmacy Program
The University of Texas at Austin College of Pharmacy
UT Health San Antonio
 
Course Faculty
 
 
Leslie Citrome, MD, MPH
Clinical Professor
Psychiatry and Behavioral Sciences
New York Medical College
Amanda J. Simonton, MSN, RN, PMHNP-BC
School of Nursing,The University of Texas at Austin
Psychiatric-Mental Health Nurse Practitioner
CARMAhealth
 
Cristyn Cordova, MSW, LCSW-S
Director of Social Work
Austin State Hospital
Dawn I. Velligan, Ph. D.
Professor
Department of Psychiatry
UT Health Science Center at San Antonio
Brendon Hogan, PharmD, BCPP
Clinical Pharmacy Manager 
Mental Health and Pain
Central Texas Veterans Health Care System
 
 
 

Faculty Financial Disclosures

  • Stephen R. Saklad, Pharm.D., BCPP has disclosed the following financial relationships: Employee of Texas Department of Health Services San Antonio;   Speakers Bureau: Actavis, Otsuka, Sunovion;   Consultant: Janssen, Jazz, Otsuka, Teva;   Other: Member of Pharmacists Foundation, Business Development Council for San Antonio 
  • Brendon Hogan, PharmD, BCPP has no relevant financial relationships to disclose.
  • Amanda J. Simonton, MSN, RN, PMHNP-BC has no relevant financial relationships to disclose.
  • Cristyn Cordova, MSW, LCSW-S has no relevant financial relationships to disclose.
  • Dawn I. Velligan, Ph. D. has disclosed the following financial relationships: Alkermes (consultant), Otsuka (advisory board, speaker), Janssen (advisory board, consulting);   on advisory boards and works as a speaker for talks that are typically disease state with a focus on adherence and recovery 
  • Leslie Citrome, MD, MPH has disclosed the following financial relationships: Performed collaborative research with, or received consulting or speaking fees from: Acadia, Alexza, Alkermes, Allergan, AstraZeneca, Avanir, BioXcel, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Forum, Genentech, Impel, Indivior, Intra-Cellular Therapies, Janssen, Jazz, Lundbeck, Luye, Meiji, Merck, Medivation, Mylan, Neurocrine, Novartis, Noven, Osmotica, Otsuka, Pfizer, Indivior/Reckitt Benckiser, Reviva, Sage, Shire, Sunovion, Takeda, Teva, Valeant, Vanda
 

Conflict Resolution

The University of Texas at Austin Continuing Pharmacy Education (UT CPE) requires instructors, planners, and other individuals who are in a position to control the content of this activity to disclose (self/spouse) all relevant financial relationships with commercial interests that are related to the content of this activity. For faculty members who reported relevant financial relationships (Saklad, Velligan, Citrome), an additional peer-review of their activity content was performed by a person who does not have any conflicts of interest.  The peer review concluded that content was evidence-based and free from commercial bias for the three speakers who reported relevant financial relationships.

Peer Review

Tawny Smith, PharmD, BCPP
Associate Professor of Psychiatry
The University of Texas at Austin Dell Medical School

  • Dr. Smith has no relevant financial relationships to disclose. 
 

Target Audience

This activity is intended for pharmacists, physicians, psychiatrists, advance practice nurses, physician assistants, psychologists, and social workers seeking an advanced level of knowledge/skills regarding the management of schizophrenia.  This program offers CPE, CME, and Social Work credit.


Fee

$0.00

CE Hours

4.25

CE Units

0.425

Activity Type

  • Knowledge

Requirements for CE Credit

 
Online modules are accredited for a total of 4.25 CE hours (credit is awarded for each individual module after it is completed, no particular sequence is required).  To earn CE credit for each online module, participants must successfully complete the pre-test (not for grade), view module content in its entirety, pass the post-test with a minimum score of 70% (< 3 attempts), and complete the module evaluation.  
Live workshop (tentatively scheduled October 14, 2020) is accredited for 3.0 CE hours (credit is only awarded for attendance of the entire 3-hr workshop). To earn CE credit for the live workshop, participants must attend the entire activity, participate in case exercises, and complete the online evaluation following the workshop.  Participants must complete the online modules before participating in the live workshop.
 
ACPE Logo
The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  The ONLINE modules are accredited up to 4.25 CE hours and the LIVE workshop is accredited for 3.0 CE hours.
 

 
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The UT Health San Antonio Joe R. & Teresa Lozano Long School of Medicine and The University of Texas at Austin College of Pharmacy. The Long San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
The Long School of Medicine designates the online activities for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
The Long School of Medicine designates the live workshop activity for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
The American Academy of Physician Assistants (AAPA), American Academy of Nurse Practitioners (AANP) and the American Nurses Credentialing Center (ANCC) accepts certificates of attendance for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
 
Healthcare professionals receiving a certificate of attendance should consult with their licensing board for information on applicability and acceptance. 
 

 
The University of Texas at Austin Hicks School of Social Work, Continuing Education Service has been approved by The University of Texas at Austin Hicks School of Social Work to offer continuing education contact hours to social workers. The University of Texas at Austin Hicks School of Social Work, Continuing Education Service has awarded up to 7.25 contact hour(s) of Continuing Social Work Education. 
 

System Requirements:
Please ensure the computer system you plan to use meets the following minimum requirements:
  • Operating System: Windows 7 or higher, macOS Sierra (10.12) or higher
  • Internet Browser: Chrome 30 or higher, Firefox 27 or higher, Internet Explorer 11, Microsoft Edge, Safari 9 or higher
  • Internet connection: Cable, High-speed DSL, and any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Media Viewing Requirements: Adobe Reader, HTML5

Education Disclaimer:
The author(s) of this continuing education activity have made reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific evidence at the time of publication. However, because information regarding medications, treatment guidelines, and other healthcare information is subject to constant change, the participant is advised to always confirm practice resources before applying any learned information in practice.Activities produced by UT Continuing Pharmacy Education are intended solely for purposes of supplementing health care professionals’ knowledge. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The University of Texas at Austin College of Pharmacy.

Support/Credits

This activity is supported in-part by an educational grant from Alkermes, Inc.   

 

 

   

Pre-Test
 
The pre-test must be completed before you can access the course content (pre-test is not graded).  Once the pre-test is submitted, please review the learning objectives and the presentation materials below.
 
Activity Details
 

Objectives

  • Discuss currently available oral/injectables medications used for schizophrenia.
  • Explain the advantages and disadvantages of each oral/injectable schizophrenia treatment.

Speaker(s)/Author(s)

Stephen R. Saklad, PharmD, BCPP picture

Stephen R. Saklad, PharmD, BCPP, Pharm.D., BCPP
Clinical Associate Professor, UT Austin College of Pharmacy / Director, Psychiatric Pharmacy Program, UT Health Science Center San Antonio , UT Austin College of Pharmacy

Activity Number

0067-9999-20-070-H01-P

Release Date: Apr 1, 2020
Credit Expiration Date: Apr 1, 2022

CE Hours

1.00
   

   

Pre-Test
 
The pre-test must be completed before you can access the course content (pre-test is not graded).  Once the pre-test is submitted, please review the learning objectives and the presentation materials below.
 
Activity Details
 

Objectives

  • Describe how to prepare patients for intramuscular injections.
  • Identify the deltoid, dorsogluteal, and ventrogluteal intramuscular injection sites.
  • Identify the steps to properly and safely administer an intramuscular injection.
  • Explain administrative technique and key considerations for intramuscular injections.

Speaker(s)/Author(s)

Amanda Simonton, MSN, RN, PMHNP-BC, MSN, RN, PMHNP-BC
PhD Candidate, Psychiatric-Mental Health Nurse Practitioner, CARMAhealth

Activity Number

0067-9999-20-072-H01-P

Release Date: Apr 1, 2020
Credit Expiration Date: Apr 1, 2022

CE Hours

0.50
   

   

Pre-Test
 
The pre-test must be completed before you can access the course content (pre-test is not graded).  Once the pre-test is submitted, please review the learning objectives and the presentation materials below.
 
Activity Details
 

Objectives

  • Define a recovery plan.
  • Describe key components of a recovery plan.
  • Identify reasons why you might choose a person-centered model.
  • Describe how a recovery plan might benefit a client's recovery.

Speaker(s)/Author(s)

Cristyn Cordova, MSW, LCSW-S
Director of Social Work, Austin State Hospital

Activity Number

0067-9999-20-073-H01-P

Release Date: Apr 1, 2020
Credit Expiration Date: Apr 1, 2022

CE Hours

0.75
   

   

Pre-Test
 
The pre-test must be completed before you can access the course content (pre-test is not graded).  Once the pre-test is submitted, please review the learning objectives and the presentation materials below.
 
Activity Details
 

Objectives

  • Describe the scope of poor adherence
  • Detail the relationships of poor adherence to poor outcomes
  • Describe how taking medication can fit into a recovery model using a shared decision-making approach

Speaker(s)/Author(s)

Dawn I. Velligan, Ph.D. picture

Dawn I. Velligan, Ph.D.
Professor of Psychiatry , The University of Texas Health San Antonio

Activity Number

0067-9999-20-074-H01-P

Release Date: Apr 1, 2020
Credit Expiration Date: Apr 1, 2022

CE Hours

1.00
   

   

Pre-Test
 
The pre-test must be completed before you can access the course content (pre-test is not graded).  Once the pre-test is submitted, please review the learning objectives and the presentation materials below.
 
Activity Details
 

Objectives

  • Discuss the tools of evidence-based medicine, namely number needed to treat and number needed to harm.
  • Evaluate medication interventions for schizophrenia using the tools of evidence-based medicine.
  • Demonstrate evidence-based interventions for individual persons with schizophrenia

Speaker(s)/Author(s)

Leslie Citrome, MD, MPH
Clinical Professor, Psychiatry and Behavioral Sciences, New York Medical College

Activity Number

0067-9999-20-076-H01-P

Release Date: Apr 1, 2020
Credit Expiration Date: Apr 1, 2022

CE Hours

1.00
   

   

Activity Details
This session is part of the Live Workshop that is scheduled to take place October 14, 2020 (time TBD)

Objectives

  • Examine oral and injectable treatments for schizophrenia using case exercises + Q/A
  • Analyze patient factors to determine whether to use a long-acting injectable or oral antipsychotic for a patient with schizophrenia
  • Apply knowledge to patient cases in regards to best form of antipsychotic to prescribe or recommend

Speaker(s)/Author(s)

Brendon Hogan, PharmD, BCPP
Clinical Pharmacy Manager - Mental Health and Pain, Central Texas Veterans Health Care System

Stephen R. Saklad, PharmD, BCPP picture

Stephen R. Saklad, PharmD, BCPP, Pharm.D., BCPP
Clinical Associate Professor, UT Austin College of Pharmacy / Director, Psychiatric Pharmacy Program, UT Health Science Center San Antonio , UT Austin College of Pharmacy

Activity Number

0067-9999-20-071-L01-P
Date: 10/14/20
Time: 12:00 PM - 12:00 PM
   

   

Activity Details
This session is part of the Live Workshop that is scheduled to take place October 14, 2020 (time TBD)

Objectives

  • Evaluate recovery plans and overcome treatment barriers in schizophrenia - case exercises + Q/A
  • Describe shared decision-making and how it differs from traditional approaches
  • Develop key components of a recovery plan
  • Identify treatment barriers and facilitators related to recovery and the recovery plan

Speaker(s)/Author(s)

Dawn I. Velligan, Ph.D. picture

Dawn I. Velligan, Ph.D.
Professor of Psychiatry , The University of Texas Health San Antonio

Stephen R. Saklad, PharmD, BCPP picture

Stephen R. Saklad, PharmD, BCPP, Pharm.D., BCPP
Clinical Associate Professor, UT Austin College of Pharmacy / Director, Psychiatric Pharmacy Program, UT Health Science Center San Antonio , UT Austin College of Pharmacy

Activity Number

0067-9999-20-075-L01-P
Date: 10/14/20
Time: 12:00 PM - 12:00 PM
   

   

Activity Details
This session is part of the Live Workshop that is scheduled to take place October 14, 2020 (time TBD)

Objectives

  • Apply evidence-based interventions in the treatment of schizophrenia + Q/A
  • Discuss which patients may benefit most from evidence-based treatments
  • Analyze patient factors to determine most appropriate treatment course based on evidence-based interventions

Speaker(s)/Author(s)

Brendon Hogan, PharmD, BCPP
Clinical Pharmacy Manager - Mental Health and Pain, Central Texas Veterans Health Care System

Stephen R. Saklad, PharmD, BCPP picture

Stephen R. Saklad, PharmD, BCPP, Pharm.D., BCPP
Clinical Associate Professor, UT Austin College of Pharmacy / Director, Psychiatric Pharmacy Program, UT Health Science Center San Antonio , UT Austin College of Pharmacy

Activity Number

0067-9999-20-077-L01-P
Date: 10/14/20
Time: 12:00 PM - 12:00 PM